REG - C4X Discovery - Board Change

C4X Discovery HoldingsAnnouncement

02/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211202:nRSB2929Ua&default-theme=true

RNS Number : 2929U  C4X Discovery Holdings PLC  02 December 2021

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Board Change

C4XD strengthens Board with the appointment of Dr Mario Polywka as Harry Finch
steps down

 

2 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, today announces the appointment of Dr Mario Polywka as a
Non-Executive Director to the Board of Directors effective from 1 December
2021.  Dr Polywka replaces Harry Finch, Non-Executive Director who has
confirmed that he will be stepping down from the Board of Directors following
the Annual General Meeting which is expected to be held in January 2022.

 

Mario joins C4XD with more than 20 years' experience in leadership roles
across the biotech industry.  Mario brings strong operational, commercial,
strategic and drug discovery expertise to the Board.  He was Chief Operating
Officer of Evotec SE for 12 years, where he was involved with transactions
worth more than
$1.0 billion within Evotec and Oxford Asymmetry International, prior to
becoming a Member of the Evotec Supervisory Board.  In addition, he holds a
number of Non-Executive Board Director positions in biotech companies
including Exscientia, Forge, Blacksmith Medicines and Orbit Discovery. Mario
studied chemistry at Oxford University, where he also completed a DPhil with
Professor Steve Davies and a postdoc with the late Professor Sir Jack Baldwin.
He is a Fellow of the Royal Society of Chemistry and has published a number of
papers in leading publications.

 

Eva-Lotta Allan, Chairman of C4X Discovery, said: "I'm delighted to welcome
Mario to C4XD. With his highly successful career in biotech and his broad
industry expertise, I am confident he will contribute significantly to the
C4XD Board of Directors, and I look forward to working with Mario on the
Board".

 

"I would very much like to take this opportunity to thank Harry on behalf of
the Board for his guidance and deep commitment to C4XD for the last 11 years.
He has been an invaluable source of support, not only to the Board, but also
to the scientific and commercial teams throughout the Company's formative
years and we wish him well with his new endeavour."

 

Dr Mario Polywka commented: "I am excited to be joining C4XD at this important
time in the Company's growth.  With two recent deals with leading
pharmaceutical companies, C4XD has clearly demonstrated the strength of its
science and its ability to commercialise it.  The C4XD Board and team are
entrepreneurial, have deep R&D expertise and are driven, and I am looking
forward to working closely with them."

 

Additional Disclosures

 

The following information is disclosed pursuant to Schedule Two paragraph (g)
of the AIM Rules of Companies.

 

Dr Mario Polywka (aged 58) holds, or has held, the following current and
former directorships in the past five years:

 

 Current Directorships      Former Directorships in the past five years
 Blacksmith Medicines Inc.  Aptuit (Oxford) Limited
 Evotec SE                  Aptuit (Potters Bar) Limited
 Exscientia Plc             Cyprotex Discovery Limited
 Forge Therapeutics Inc.    Cyprotex Limited
 Obit Discovery Ltd         Euprotec Limited
 Orbit Discovery Group Ltd  Evotec (UK) Limited
                            Exscientia AI Limited
                            Panion Limited
                            Pharminox Ltd
                            T-Cypher Bio Limited

 

Save as set out above, no further information regarding Dr Mario Polywka is
required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM
Rules for Companies.

 

- Ends -

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world leading medicines, which are developed by our
partners for the benefit of patients. We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early stage novel target
opportunities to late stage Drug Discovery programmes ready for out-licensing
to partners and we have two commercially partnered programmes with one
candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development. Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAVFLFBFLLLFBB